Summary
Acute myeloid leukemia, a common form of leukemia with a high mortality rate, is difficult to treat. In the SORAML trial, sorafenib, a multikinase inhibitor, prolonged event-free and relapse-free survival compared with a placebo in younger patients with acute myeloid leukemia. However, this benefit was accompanied by a higher rate of infections and bleeding.
- overall survival
- event free survival
- relapse free survival
- infection
- bleeding
- sorafenib
- placebo
- Study Evaluating Sorafenib Added to Standard Primary Therapy in Patients With Newly Diagnosed Acute Myeloid Leukemia Less Than 60 Years of Age
- SORAML
- NCT00893373
- © 2014 SAGE Publications
Tools
Sorafenib as Effective Treatment for Newly Diagnosed AML in Younger Patients
Permalink:
Table of contents
Cited By...
- No citing articles found.